Meet ODEON Turmeric Face Pack: A Trusted Ritual, Reimagined for Modern Skin
Odeon, the global skincare brand trusted in over 30 countries, has just unveiled its first-ever face pack in India and it's a beautiful blend of the past and the present.
Inspired by generations of Indian skincare wisdom, this Turmeric & Mineral Clay Face Pack merges heritage skincare with science-backed formulations. With this launch, Odeon adds to its face care range with a formula that strips away the noise and focuses on what really works.
What's inside:
• Turmeric – to calm, brighten, and revive dull skin
• Bentonite & Kaolin Clays – to detox, decongest, and reduce excess oil
• Niacinamide, Vitamin C & E, Glycerin – for hydration, barrier repair, and glow
Free from parabens, sulphates, silicones and designed specifically for oily and combination skin, this turmeric face pack is your weekly refresh in under 15 minutes.
Whether you're dealing with pollution, oil imbalance, or just tired skin, this pack is designed to fit easily into your routine.
'We wanted this to feel like something you already trust, just made easier, more consistent and effective,' said a spokesperson for Odeon.
Available in 10ml single-use sachets (perfect for travel or trial) and 50ml tubes for your weekly self-care ritual.
Building for the modern Indian routine
The launch comes at a time when consumers are increasingly moving toward minimalist, effective skincare, especially in smaller cities, where price and familiarity remain key decision drivers. With this dual-format launch, Odeon continues to champion ingredient-led care and simplicity over clutter, building its core identity around 'real care and real results'.
The brand looks to deepen its local relevance while staying consistent with its global focus on ingredient transparency, safety, and simplicity.
Exclusively available in India before anywhere else!
The Odeon Turmeric & Mineral Clay Face Pack is now available on www.odeonworld.com, and in offline stores across India.
(Disclaimer: The above press release comes to you under an arrangement with NRDPL and PTI takes no editorial responsibility for the same.). PTI
This is an auto-published feed from PTI with no editorial input from The Wire.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fashion Value Chain
13 minutes ago
- Fashion Value Chain
Wonderful Pistachios Highlights Power of Protein at Indian Healthy Snacking Summit 2025
Wonderful Pistachios, the world's largest grower and processor of pistachios and distributor of California Pistachios, proudly participated as an exhibitor, partner and speaker at the Indian Healthy Snacking Summit (IHSS) 2025, held in Delhi under the theme 'The Future of Snacking, One Bite at a Time.' The summit brought together leading voices and innovative minds from the food ecosystem, including startups, industry leaders, and health and wellness experts to explore the future of India's evolving snacking culture. Shail Pancholi, Spokesperson for California Pistachios Representing Wonderful Pistachios, Shail Pancholi, spokesperson for California Pistachios in India, delivered a powerful presentation that tracked the brand's global journey in transforming pistachios from a humble commodity into a modern-day, high-protein snack. He shared how Wonderful Pistachios became the #1 snack nut brand in the U.S., driven by a sharp focus on health, taste, and innovation. Pancholi drew compelling parallels between global snacking trends and India's rapidly evolving consumer behaviour. 'Indian consumers are increasingly looking for snacks that are not only delicious but also functional and protein-smart,' he stated, spotlighting pistachios as a balanced snacking source-containing all nine essential amino acids-and comparing them to other plant-based proteins like tofu, lentils, and chickpeas in protein quality (as presented in the comparative index from the presentation). Pancholi also spoke about the brand's targeted digital and out-of-home campaign in India last year, which helped establish pistachios as a go-to snack among urban health-conscious consumers. The summit also witnessed the launch of Farmleys Healthy Snacking Report 2025, which revealed that 'Health has emerged as a key driver in snacking decisions, with 72% of respondents actively seeking snacks that offer functional benefits such as improved energy, enhanced mood, and higher protein content.' California Pistachios tie into this trend as a smart snack that provides six grams of protein per 28g serving, as well as giving consumers energy to power their day. Other notable speakers at IHSS included Revant Himatsingka (Food Pharmacist), Ambrish Jha (CEO, SatyaG), Sanjay Jakhar (IIMR), Amish Srivastava (SVP, Bigbasket), and representatives from Shark Tank India-each offering insights into the future of food and functional snacking. As India continues to embrace purposeful, health-driven snacking, Wonderful Pistachios remains committed to leading the charge by offering a snack that doesn't force consumers to choose between taste and nutrition. For more information about California Pistachios, visit California Pistachios California Pistachios are grown and distributed by The Wonderful Company, the worlds largest vertically integrated pistachio processor and marketer located in Californias Central Valley. California Pistachios are Non-GMO, providing a smart, healthy choice for consumers around the world. Sun-ripened in the moderate Mediterranean climate of California, these distinctively green nuts pack taste and contain antioxidants and over 30 different nutrients. California Pistachios in India are available under leading brands and private labels at retail outlets, grocery stores, and online platforms.
The Print
13 minutes ago
- The Print
Lilly launches Mounjaro pen in India at Rs. 14,000 for starting dose, stepping up Novo rivalry – ThePrint
Mounjaro Kwikpen is available in six dose strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg — with pricing calculated for a month's supply. Lilly said in June it received approval from India's drug regulator for its once-weekly Mounjaro Kwikpen, two days after Novo Nordisk launched Wegovy in multiple dose strengths in a similar pen device. Hyderabad: Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees (nearly $160) for its starting dose of 2.5 mg in India, stepping up competition with Novo Nordisk. The smallest two doses are priced at 14,000 and 17,500 rupees, respectively, and the 7.5 mg and 10 mg doses cost 22,000 rupees. The 12.5 mg and 15 mg doses cost 27,500 rupees, the company said. 'If we look at how the highest doses of Mounjaro and Wegovy are priced, it appears (that) Mounjaro's pricing is attractive and competitive,' said Vishal Manchanda from Systematix Institutional Equities. Wegovy's smallest doses of 0.25 mg, 0.5 mg and 1 mg cost 17,345 rupees a month, and its highest doses of 1.7 mg and 2.4 mg cost 24,280 rupees and 26,015 rupees a month, respectively. Lilly began selling Mounjaro in India in late March for diabetes and obesity in 2.5 mg and 5 mg vials. Both drugs have seen strong demand since then, with sales in July doubling month-on-month. The drugs belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer. ($1 = 87.6650 Indian rupees) (Reporting by Kashish Tandon in Bengaluru and Rishika Sadam in Hyderabad; Editing by Janane Venkatraman) This report is auto-generated from Reuters news service. ThePrint holds no responsibility for its content.
News18
21 minutes ago
- News18
Max Healthcare Q1 profit up 17 pc at Rs 345 cr
Last Updated: New Delhi, Aug 13 (PTI) Max Healthcare Institute on Wednesday said its profit after tax increased 17 per cent year-on-year to Rs 345 crore for June quarter FY26 on enhanced utilisation of operational beds across the hospital network. The healthcare major reported a profit after tax (PAT) of Rs 295 crore in the April-June period last year. Gross revenue rose to Rs 2,574 crore in the quarter from Rs 2,028 crore in the year-ago period, Max Healthcare said in a statement. Net debt at June-end stood at Rs 1,755 crore as compared with Rs 1,576 crore on March 31, 2025. The company said its board has approved execution of an agreement to lease a built-to-suit 130-bed hospital in Dehradun. The proposed facility will be located near the company's existing 220-bed hospital, which is operational since 2012. Scheduled for commissioning in 2028, the new hospital will, among other specialties, focus on advanced oncology services, including radiation therapy, it said. Besides, Jaypee Healthcare Ltd, a wholly-owned subsidiary, has executed a binding term sheet to divest Chitta (Bulandshahr) and Anoopshahr hospitals to Manush Aushadi and Anusandan Ltd for Rs 40 crore, subject to working capital adjustment at closing. This move is in line with the company's strategy to concentrate on super-specialty care in larger cities, it said. 'Our sustained growth is a reflection of our strategy and execution capabilities," Max Healthcare Institute Chairman and Managing Director Abhay Soi said. The commissioning of 160-bed brownfield tower at Max Mohali, along with additional brownfield capacities coming online at Max Smart and Nanavati-Max shortly, will significantly enhance clinical and financial performance of the network, he added. 'In parallel, we are scaling up our clinical and support teams, while optimizing our service mix to ensure rapid and effective utilisation of the new capacities," Soi stated. Shares of the company were trading 0.24 per cent up at Rs 1,265 apiece on BSE. PTI MSS MSS ANU ANU view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
